Affinia Therapeutics Inc, a devastating disease therapy developer, has filed Form S-1 Registration Statement on January 4, 2022 with the U.S. Securities and Exchange Commission to raise up to $100 million IPO. Pricing terms are yet to announce.
The company is a preclinical stage company pioneering a new class of rationally designed gene therapies with potentially curative benefit in patients with both rare and prevalent devastating diseases. Their rationally designed gene therapy candidates are methodically created to address the key limitations of current approaches and to meet the specific needs of a disease.
The Waltham, Massachusetts-based company was founded in 2019 and booked $8 million in collaboration revenue for the 12 months ended September 30, 2021. It plans to list on the Nasdaq Global Market under the symbol “AFTX.” Goldman Sachs, Jefferies, Piper Sandler, and Chardan Capital Markets are underwriters of the IPO.
The company engages Cooley LLP as US Securities Counsel, and Deloitte & Touche LLP as Independent Auditor.
#ipo #nasdaq #AffiniaTherapeutics #AFTX #gene #devastating #diseases
Hexcellence Consulting has experienced IPO consulting team focus on listing in US Stock Market,
namely NYSE, Nasdaq and OTC Markets.
Should you interested to list your company in US Stock Market,
please contact us at [email protected]
